Pipeline

Our precisely delivered therapies – with their favorable tolerability profiles and systemic immunotherapeutic effects – have the potential to significantly improve survival while maintaining quality of life throughout all stages of disease.

We are evaluating our oncolytic viral immunotherapies in a variety of solid tumors, including prostate, brain, lung and pancreatic cancer. For more information on our clinical studies, please visit our Clinical Trials page.

PROGRAM

INDICATION

PRECLINICAL

PHASE I

PHASE II

PHASE III

Adenovirus Platform

CAN-2409
Prostate Cancer

Localized, Intermediate/High Risk, under SPA

Active Surveillance

Localized, Intermediate/High Risk, under SPA

Phase III

Intermediate/High Risk, under SPA - Phase 3

Active Surveillance

Phase II

Active Surveillance Patients - Phase 2

CAN-2409
Brain Cancer

1L High-Grade Glioma

1L High-Grade Glioma + Opdivo®

1L High-Grade Glioma

Phase III

Upfront Glioblastoma - Phase 3

1L High-Grade Glioma + Opdivo®

Phase I

Upfront Glioblastoma + Opdivo® - Phase 1

CAN-2409
Lung Cancer

NSCLC + PD-1/PD-L1

NSCLC + PD-1/PD-L1

Phase II

NSCLC + PD-1/PD-L1 - Phase 2

CAN-2409
Pancreatic Cancer

Advanced Non-Metastatic Pancreatic Adenocarcinoma

Advanced Non-Metastatic Pancreatic Adenocarcinoma

Phase II

Advanced Non-Metastatic Pancreatic Adenocarcinoma - Phase 2

HSV Platform

CAN-3110
Brain Cancer

Recurrent High-Grade Glioma

Recurrent High-Grade Glioma

Phase I

Recurrent GBM - Phase 1

Discovery Programs

Undisclosed

Undisclosed

Phase I

Undisclosed - Preclinical

© 2021 by Candel Therapeutics